Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials.
Eric P BorrelliConor G McGladriganPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
This analysis helps to highlight the importance of conducting postmarketing pharmacovigilance studies to better understand the potential adverse reactions of these medications.